Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABPNASDAQ:ACGNNASDAQ:BRTXNASDAQ:NXTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.21-0.1%$0.24$0.15▼$13.00$12.69M-0.035.02 million shs3.03 million shsACGNAceragen$0.38$0.46$0.36▼$16.00N/AN/AN/AN/ABRTXBiorestorative Therapies$1.58-7.1%$1.74$1.21▼$2.55$11.86M76.75146,533 shs96,772 shsNXTCNextCure$0.47+3.8%$0.46$0.22▼$1.82$13.18M1.07124,608 shs163,947 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro0.00%-2.93%-1.56%-56.26%+20,869,900.00%ACGNAceragen0.00%0.00%0.00%0.00%0.00%BRTXBiorestorative Therapies0.00%-5.95%-4.82%-19.80%-22.17%NXTCNextCure0.00%-30.98%-7.44%-22.82%-70.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/AACGNAceragenN/AN/AN/AN/AN/AN/AN/AN/ABRTXBiorestorative Therapies3.7093 of 5 stars3.55.00.00.03.13.30.6NXTCNextCure4.5103 of 5 stars3.55.00.04.31.71.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,816.63% UpsideACGNAceragen 0.00N/AN/AN/ABRTXBiorestorative Therapies 3.00Buy$18.001,039.24% UpsideNXTCNextCure 3.00Buy$3.50644.68% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$180K70.48N/AN/A($0.29) per share-0.72ACGNAceragen$4.86M0.66N/AN/AN/A∞BRTXBiorestorative Therapies$391K30.33N/AN/A$1.23 per share1.28NXTCNextCureN/AN/AN/AN/A$2.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbpro-$7.23MN/A0.00∞N/AN/AN/A-198.95%N/AACGNAceragen-$23.36MN/A0.00∞N/AN/AN/AN/AN/ABRTXBiorestorative Therapies-$8.98M-$1.47N/AN/AN/A-3,093.61%-129.47%-86.02%8/12/2025 (Estimated)NXTCNextCure-$55.65M-$1.76N/AN/AN/AN/A-70.16%-58.10%7/30/2025 (Estimated)Latest ACGN, BRTX, ABP, and NXTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/AABPAbproN/A-$0.08N/A-$0.08N/AN/A5/14/2025Q1 2025BRTXBiorestorative Therapies-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 million5/1/2025Q1 2025NXTCNextCure-$0.40-$0.39+$0.01-$0.39N/AN/A3/27/2025Q4 2024BRTXBiorestorative Therapies-$0.27-$0.20+$0.07-$0.20$0.48 million$0.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/AACGNAceragenN/AN/AN/AN/AN/ABRTXBiorestorative TherapiesN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/A0.110.11ACGNAceragenN/AN/AN/ABRTXBiorestorative TherapiesN/A2.242.24NXTCNextCureN/A10.2610.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%ACGNAceragen0.05%BRTXBiorestorative Therapies69.38%NXTCNextCure42.65%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%ACGNAceragen26.45%BRTXBiorestorative Therapies25.50%NXTCNextCure13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1560.79 million48.14 millionN/AACGNAceragen268.42 million6.20 millionNot OptionableBRTXBiorestorative Therapies77.51 million5.59 millionNot OptionableNXTCNextCure9028.05 million24.32 millionOptionableACGN, BRTX, ABP, and NXTC HeadlinesRecent News About These CompaniesNextcure stock drops near 30% on $745M ADC deal with SimcereJune 18, 2025 | bioworld.comNextCure Joins China-ADC Gold Rush with $745M Simcere DealJune 17, 2025 | biospace.comNextCure tanks as it teams up with Simcere on novel ADCJune 17, 2025 | thepharmaletter.comNextCure advances ADC pivot with $745M deal for Simcere’s phase 1 drugJune 16, 2025 | fiercebiotech.comNextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% DeclineJune 16, 2025 | msn.comNextCure signs up to $745 million deal with China's Simcere to develop cancer drugJune 16, 2025 | reuters.comNextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6June 16, 2025 | globenewswire.comNextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ...May 30, 2025 | morningstar.comNextCure, Inc. and LigaChem Biosciences Announce Phase 1 Study of LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, to be Presented at ASCO 2025May 30, 2025 | nasdaq.comNextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024May 30, 2025 | insidermonkey.comNextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025May 29, 2025 | globenewswire.comNextCure Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 2, 2025 | taiwannews.com.twNextCure Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 1, 2025 | globenewswire.comNextCure to Present at 24th Annual Needham Virtual Healthcare ConferenceApril 4, 2025 | globenewswire.comH.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74March 17, 2025 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for NextCure (NXTC)March 8, 2025 | markets.businessinsider.comNextCure Reports 2024 Financials and Strategic ProgressMarch 7, 2025 | tipranks.comNextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill CohortsMarch 6, 2025 | quiverquant.comNextCure Provides Business Update and Reports Full Year 2024 Financial ResultsMarch 6, 2025 | globenewswire.comNextCure stock plunges to 52-week low, hits $0.69February 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACGN, BRTX, ABP, and NXTC Company DescriptionsAbpro NASDAQ:ABP$0.21 0.00 (-0.14%) As of 06/20/2025 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.Aceragen NASDAQ:ACGNAceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.Biorestorative Therapies NASDAQ:BRTX$1.58 -0.12 (-7.06%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.61 +0.03 (+1.90%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.NextCure NASDAQ:NXTC$0.47 +0.02 (+3.84%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.48 +0.01 (+1.91%) As of 06/20/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
